metricas
covid
Buscar en
Medicina Clínica
Toda la web
Inicio Medicina Clínica Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible...
Journal Information
Vol. 162. Issue 12.
Pages e70-e73 (June 2024)
Share
Share
Download PDF
More article options
Visits
7
Vol. 162. Issue 12.
Pages e70-e73 (June 2024)
Review
Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible?
Diagnóstico temprano en la amiloidosis ATTRv. ¿Qué tan temprano es suficiente? ¿Qué tan temprano es posible?
Visits
7
Isabel Conceiçãoa,b
a Departamento de Neurociências e Saúde Mental, Unidade Local de Saúde de Santa Maria, Hospital de Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal
b Instituto de Fisiologia, Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Portugal
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Special issue
This article is part of special issue:
Transthyretin amyloidosis

Edited by: Dr. Juan González Moreno - Hospital Universitario, Spain. Dra. Inés Losada López - Hospital Universitario, Spain

More info
Abstract

Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare, progressive, and debilitating genetic disorder characterized by the deposition of abnormal transthyretin (TTR) protein aggregates in various tissues, leading to organ dysfunction. Early diagnosis of ATTRv amyloidosis is critical for starting timely interventions and improving patient outcomes. This review explores the concepts of “how early is enough” and “how early is possible” in the context of diagnosing ATTRv amyloidosis, highlighting the challenges and opportunities for early recognition.

Keywords:
Hereditary transthyretin amyloidosis
Early diagnosis
Challenges in diagnosis
Resumen

La amiloidosis hereditaria por transtiretina (ATTRv amiloidosis) es un trastorno genético inusual, progresivo y debilitante caracterizado por el depósito de agregados anormales de proteína transtiretina (TTR) en varios tejidos, lo que lleva a disfunción orgánica. El diagnóstico precoz de la ATTRv amiloidosis es crucial para iniciar intervenciones oportunas y mejorar los resultados del paciente. Esta revisión explora los conceptos de «¿qué tan temprano es suficiente?» y «¿qué tan temprano es posible?» en el contexto del diagnóstico de la ATTRv amiloidosis, destacando los desafíos y oportunidades para el reconocimiento precoz.

Palabras clave:
Amiloidosis hereditaria por transtiretina
Diagnóstico precoz
Desafíos en el diagnóstico

Article

These are the options to access the full texts of the publication Medicina Clínica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcli.2022.10.002
No mostrar más